Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 11/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15017323 | 0.79 | TRPA1 (0.41) | AXLMETAP2TRPA1TRPM8TRPV1 | |
| SCHEMBL20389635 | 0.73 | FGFR1 (0.39) | — | |
| SCHEMBL30536638 | 0.70 | AXL (0.54) | AXLMETAP2TRPA1TRPM8TRPV1 | |
| SCHEMBL12684216 | 0.69 | GRK2 (0.41) | JAK2JAK3 | |
| SCHEMBL16291966 | 0.68 | AXL (0.51) | AXLMETAP2TRPA1JAK2 | |
| SCHEMBL14769543 | 0.68 | GRK2 (0.40) | — | |
| SCHEMBL14767819 | 0.66 | TSHR (0.49) | AXL | |
| SCHEMBL14879442 | 0.64 | ALDH1A1 (0.69) | — | |
| SCHEMBL30911386 | 0.64 | TRPA1 (0.43) | AXLMETAP2TRPA1TRPM8TRPV1 | |
| SCHEMBL30901286 | 0.64 | BACE1 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791137-B1 | PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION PROCESS THEREFOR AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2019-01-23 | — | — | EP | disclosed |
| US-10138235-B2 | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof | SANOFI (FR) | 2018-11-27 | — | — | US | disclosed |
| US-20170231998-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | SANOFI (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170174681-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | SANOFI (FR) | 2017-06-22 | — | — | US | disclosed |
| US-20140350006-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174681-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | FGF1, FGF2, FGFR1 | AXL 780/4885METAP2 449/4885TRPA1 3187/4885 |
| US-10138235-B2 | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof | FGF1, FGF2, FGFR1 | AXL 780/4885METAP2 449/4885TRPA1 3187/4885 |
| US-20170231998-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | FGF1, FGF2, FGFR1 | AXL 780/4885METAP2 449/4885TRPA1 3187/4885 |
| US-20140350006-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | FGF1, FGF2, FGFR1 | AXL 780/4885METAP2 449/4885TRPA1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.